Tokyo, Sept. 23 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059162) titled 'A study on the effectiveness of a novel preservative fluid (CytoRich Red) for diagnosing pancreatic tumor using endoscopic ultrasound' on Sept. 22.
Study Type:
Observational
Primary Sponsor:
Institute - Yokohama City Minato Red Cross Hospital
Condition:
Condition - pancreatic tumor
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - To prospectively evaluate the diagnostic yield of endoscopic ultrasound-guided tissue acquisition (EUS-TA) using BD CytoRich Red preservative fluid for pancreatic tumor.
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 18
years-old
=
Gender - Male and Female
Key inclusion criteria - Patients undergoing endoscopic ultrasound-guided tissue acquisition (EUS-TA) for pancreatic tumors at our hospital between April 2025 and March 2028
Patients who provide written informed consent to participate in the study after receiving an adequate explanation and fully understanding the details
Key exclusion criteria - Patients who are medically ineligible for EUS-TA
Patients deemed inappropriate for participation in this study by the principal investigator or co-investigators
Target Size - 110
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2025 Year 04 Month 04 Day
Date of IRB - 2025 Year 04 Month 04 Day
Anticipated trial start date - 2025 Year 04 Month 05 Day
Last follow-up date - 2028 Year 10 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066146
Disclaimer: Curated by HT Syndication.
